These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26189252)

  • 1. Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction.
    Grabowskil JP; Mardas M; Markowska A; Markowska J
    Eur J Gynaecol Oncol; 2015; 36(3):274-7. PubMed ID: 26189252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer.
    Yildirim Y; Ertas IE; Nayki U; Ulug P; Nayki C; Yilmaz I; Gultekin E; Dogan A; Aykas A; Ulug S; Ozdemir A; Solmaz U
    Eur J Gynaecol Oncol; 2014; 35(4):400-7. PubMed ID: 25118481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
    Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laparoscopic staging for apparent stage I epithelial ovarian cancer.
    Melamed A; Keating NL; Clemmer JT; Bregar AJ; Wright JD; Boruta DM; Schorge JO; Del Carmen MG; Rauh-Hain JA
    Am J Obstet Gynecol; 2017 Jan; 216(1):50.e1-50.e12. PubMed ID: 27567562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Iyer RB; Zhou Q; Iasonos A; Denesopolis J; Zivanovic O; Long Roche KC; Sonoda Y; Coleman RL; Abu-Rustum NR; Hricak H; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):27-31. PubMed ID: 28209497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
    Sørensen SM; Schnack TH; Høgdall C
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Martinez A; Pomel C; Mery E; Querleu D; Gladieff L; Ferron G
    Gynecol Oncol; 2011 May; 121(2):258-63. PubMed ID: 21295334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY).
    Uccella S; Nero C; Vizza E; Vargiu V; Corrado G; Bizzarri N; Ghezzi F; Cosentino F; Turco LC; Fagotti A; Scambia G
    Am J Obstet Gynecol; 2019 Oct; 221(4):324.e1-324.e10. PubMed ID: 31082385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laparoscopic Versus Laparotomic Surgical Staging for Early-Stage Ovarian Cancer: A Case-Control Study.
    Gallotta V; Petrillo M; Conte C; Vizzielli G; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Carbone V; Scambia G
    J Minim Invasive Gynecol; 2016; 23(5):769-74. PubMed ID: 26995493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
    Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
    Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
    Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
    Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
    Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
    Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
    Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
    Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.